As of yet, there are no approved therapies that successfully target triglyceride-rich lipoproteins and remnants, which are often elevated in diabetes, but inhibition of Apolipoprotein C3 (APOC3) or Angiopoietin-like 3 (ANGPTL3) has, in clinical trials, been shown to reduce triglycerides and triglyceride-rich lipoproteins (73–76). This evidence concerns the gene APOC3 and diabetes mellitus.